News

Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna
Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.
This biotech's stock rockets on oral obesity drug partnership with Wegovy parent
Shares of Septerna Inc. were soaring in early Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...
Novo Nordisk, Septerna in $2.2 Billion Obesity Pill Partner Deal
Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity and type-2 diabetes ...
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments
Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...
Devdiscourse3h
Novo Nordisk and Septerna Team Up for Groundbreaking Obesity Treatments
Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...
STAT3h
Novo Nordisk strikes deal with Septerna to develop obesity pills
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Health Rounds: Study suggests lower Wegovy dose might be just as effective
Cuban annual raw sugar production will fall below 200,000 metric tons in 2025 for the first time since the 19th century, ...
'Golden age' of weight loss drugs coming – see which are about to get a lot cheaper
Scientists herald 150 new jabs and pills to tackle obesity going through the research pipeline - but issue urgent warning to ...
Elon Musk’s AI Chatbot Thinks Trump’s Hilarious ‘Fat’ Businessman Story Was All About Him
Elon Musk is President Trump’s “seriously overweight” friend who takes “the fat shot,” according to the Tesla CEO’s own artificial intelligence bot. Trump was discussing plans to lower medication ...